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Background: Reduced muscle mass is a hallmark of metabolic diseases like diabetes and cancer. The mammalian
(mechanistic) target of rapamycin complex 1/S6 kinase 1 (mTORC1/S6K1) pathway is critical to the regulation of
muscle protein synthesis and mass but its mechanism of action is not completely understood.
Results: Using L6 myotubes, we characterized the regulation of programmed cell death 4 (PDCD4), a recently
described substrate of S6K1. The abundance, but not Ser67 phosphorylation, of PDCD4 was sensitive to amino acid
and serum deprivation: values in starved cells were 4.5X of control (P < 0.001). Refeeding had opposite effects.
Growth factors, compared to amino acids, appeared more critical in regulating PDCD4 abundance. Furthermore,
inhibition of mTORC1 or the proteasome prevented the refeeding-associated decrease in PDCD4 abundance. Amino
acid and serum deprivation significantly increased PDCD4 binding to eIF4A (P < 0.05); this was reversed during
refeeding. PDCD4 depletion by RNA interference had no significant effect on phenylalanine incorporation into
myotube mixed proteins in control cells but further suppressed (30%) this measure in nutrient-deprived cells
(P < 0.0005). This was not observed in myoblasts. In starved myotubes, PDCD4 depletion further reduced the
association of eIF4G with eIF4E.
Conclusion: Our data suggest that in myotubes, PDCD4 abundance is sensitive to nutritional manipulation in an
mTORC1 and proteasome depended manner. Furthermore, the role of PDCD4 in regulating protein synthesis
appears dependent on the developmental state of the cell.
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The mammalian (mechanistic) target of rapamycin com-
plex 1/ribosomal protein S6 kinase 1 (mTORC1/S6K1)
signalling is a critical regulator of skeletal muscle mass
and metabolism, and mechanisms that regulate it are stud-
ied as possible targets for the treatment/prevention of loss
of muscle mass in diverse muscle atrophying conditions
[1,2]. However, the exact mechanism by which S6K1 regu-
lates muscle mass and metabolism remains to be identi-
fied. Substrates of S6K1 proposed to mediate its actions
are all factors that associate with or regulate mRNA trans-
lation initiation. These include the ribosomal protein S6
(S6) and the eukaryotic mRNA translation initiation factor
4B (eIF4B), both of which upon activation induce mRNA
translation initiation. S6K1 also phosphorylates eukaryotic
mRNA translation elongation factor 2 (eEF2) kinase, an* Correspondence: oadegoke@yorku.ca
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stated.inhibitor of mRNA translation (reviewed in [3,4]). In
skeletal muscle, concurrent increase in phosphorylation
of S6K1, S6 and eIF4B are observed in conditions that
stimulate muscle protein synthesis, including resistance
exercise, provision of amino acid, and stimulation with
insulin/IGF-1 [1,5,6]. However, the functions/regulation
of these substrates do not account for the actions of S6K1
in controlling mRNA translation initiation and muscle
mass [6,7], suggesting a role for other substrates of this
kinase.
Programmed cell death 4 (PDCD4), (also known as
MA3, TIS (topoisomerase inhibitor-suppressed) [8], H731
[9], and interleukin-12 inducible human gene 197/15a [10]
(reviewed in [11])), is a more recently discovered substrate
of S6K1 [12]. In the hypo phosphorylated state, it binds to
both eIF4A and eIF4G, leading to both the inhibition of
the helicase activity of eIF4A and of the formation of
eIF4F complex. These changes will lead to the suppression
of translation of mRNA with secondary structures at theirLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Figure 1 In L6 myotubes, PDCD4 abundance, but not
phosphorylation, is sensitive to medium nutrient composition
and requires mTORC1 function. L6 Myotubes were incubated in
differentiation (Ctl) or starvation medium (serum-free, amino acid-free
RPMI medium) for 12 h. They were then harvested (Stv) or refed in
the differentiation medium supplemented with DMSO (−) or 50 nM
rapamycin (+) for 1 or 3 h. (A) Phosphorylated (ph) and total
PDCD4 (Ser67), ph-S6K1 (Thr389) and γ-tubulin were analyzed by
immunoblotting. (B and C) phosphorylated and total PDCD4 signals
were expressed relative to γ tubulin. Means ± SE of 5–6 independent
experiments; bars with different letters differ (P < 0.05).
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S6K1 phosphorylates Ser67 in PDCD4. This targets it
for ubiquitination by the ubiquitin protein ligase beta-
transducin repeat containing protein (β-TRCP) and sub-
sequent degradation by the proteasome [12].
Much of what is known about PDCD4 is from cancer
studies where PDCD4 is proposed to function as a cell
cycle inhibitor/tumor suppressor. Loss of this protein is
associated with invasion, progression or increased aggres-
sion of numerous, but not all [15], cancers, including ovar-
ian [16], lung [17], breast [18], liver [19] and colon cancers
[11]. As a substrate of mTORC1/S6K1, PDCD4 may me-
diate the effect of this kinase pathway on protein synthesis
in skeletal muscle. However, not much is known about the
role or regulation of PDCD4 in muscle, the tissue that is
quantitatively the most important in whole body protein
metabolism. It was recently shown that the abundance of
PDCD4 in rat skeletal muscle is sensitive to feeding and
food deprivation cycle: its abundance increased in skeletal
muscle of food-deprived rats, but in fed or refed rats, its
abundance decreased along with increase in muscle
fractional protein synthesis [20]. These data suggest that
interventions that regulate PDCD4 abundance may be
explored in the treatment of muscle wasting, a feature
of diseases like cancer, AIDS, and trauma. However this
study was mainly correlative and did not examine whether
or not mTORC1/S6K1 is required for PDCD4 regulation
in muscle.
In the present work, using L6 myotubes, our specific ob-
jectives were to: 1) examine the requirement for mTORC1/
S6K1 and the ubiquitin proteolytic system in regulating
PDCD4; 2) examine the contribution of amino acids vs.
growth factors in mediating the effect of nutrition on
PDCD4; and 3) determine whether nutritional status af-
fects the interaction of PDCD4 with components of eIF4F.
Because others have suggested that signalling pathways
that regulate protein metabolism may be regulated differ-
ently in myotubes versus myoblasts [21] and because the
regulation of PDCD4 may depend on cell type [22], we
also assessed the effect of PDCD4 depletion by RNA inter-
ference (RNAi) on myotube total and myofibrillar protein
synthesis.
Results
Abundance of PDCD4 in L6 myotubes is sensitive to
medium composition and requires mTORC1 and the
proteasome
Given the identification of PDCD4 as a substrate of
mTORC1/S6K1 signalling, and the fact this kinase
pathway is regulated by nutrients, we examined the ef-
fect of nutrient deprivation on the regulation PDCD4
in L6 myotubes. Neither 12 h of serum and amino acid
deprivation nor refeeding in a complete medium had
any significant effect on PDCD4 Ser67 (the residuetargeted by S6K1) phosphorylation (Figure 1A, B). Fur-
thermore, serum and amino acid deprivation had no
effect on phosphorylation on Ser457, although phos-
phorylation on this residue was increased by refeeding
(see Additional file 1). However, PDCD4 abundance in-
creased more than four-fold in starved cells and decreased
progressively with time during refeeding such that by 3 h
of refeeding, values in re-fed cells were not different from
control (P < 0.05, Figure 1A, C). Incubation with rapa-
mycin, an mTORC1 inhibitor, abolished the effect of re-
feeding on PDCD4 abundance (Figure 1A, C).
Because the ubiquitin system is implicated in the
phosphorylation-dependent degradation of PDCD4, we
incubated the cells with MG132, a proteasome inhibitor.
PDCD4
Starvation followed by refeeding in:
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Figure 3 Growth factors, but not amino acids, promote the
degradation of PDCD4. L6 myotubes were incubated in
differentiation (Ctl) or starvation medium as described in Figure 1.
They were then harvested (Stv) or refed in the differentiation
medium (DM), serum-free AMEM (AMEM), or in starvation medium
supplemented with either 0.4 mM leucine (LEU), 10% dialyzed FBS
(FBS) or 2% horse serum (HS) for 1 h. (A) Cells were harvested and
analyzed by immunoblotting. (B) PDCD4 signals were quantified and
expressed relative to γ-tubulin. Means ± SE; n = 4; bars with different
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appearance of PDCD4 during re-feeding (Figure 2A, B).
Growth factors, but not amino acids, regulate PDCD4
abundance
The experiments above did not indicate whether the ob-
served effects of refeeding were due to nutrients or growth
factors. To address this question, we repeated the starva-
tion experiment but re-fed the myotubes in either the
differentiation medium, serum-free AMEM, or starvation
medium supplemented with leucine, dialyzed FBS or horse
serum. Only media that contained serum promoted the
degradation of PDCD4 (Figure 3A, B).
Association of PDCD4 with eIF4A in L6 myotubes is
sensitive to medium composition
PDCD4 inhibits mRNA translation initiation at least in
part by its binding to eIF4A and eIF4G. The amount of
PDCD4 found in eIF4A immunoprecipitate was increased
by starvation but fell gradually during refeeding, especially
at 3 h, at which time the values were not different from
those observed in fed cells (Figure 4A, B). In another ex-
periment, we carried out the reciprocal immunoprecipita-
tion. The amount of eIF4A in PDCD4 immunoprecipitate
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Figure 2 Abundance of PDCD4 in myotubes is regulated by the
proteasome. L6 myotubes were incubated in differentiation (Ctl) or
starvation medium as described in Figure 1. They were then
harvested (Stv) or refed in the differentiation medium supplemented
with DMSO (−) or 10 μM MG132 (+) for 1 or 3 h. (A) Total PDCD4
and γ tubulin were analyzed by immunoblotting. (B) PDCD4 signals
were quantified and expressed relative to γ-tubulin. Means ± SE;
n = 4–6; bars with different letters differ (P < 0.05).
letters differ (P < 0.05).increased PDCD4 abundance in the immunocomplex, the
ratio of eIF4A to PDCD4 was suppressed by starvation.
This was reversed by refeeding (Figure 4C-D). In addition,
the pattern of eIF4G association with PDCD4 was similar
to that observed for eIF4A; however, the effect of refeeding
was not seen until the 3 h time point (Figure 4C and 4E).
Finally we examined the effects of mTORC1 inhibition on
the interactions. In all cases, the effect of refeeding on the
interactions of PDCD4 with eIF4A and 4G was sensitive
to rapamycin (Figure 4A-E).
PDCD4 depletion in myotubes had modest effect on
protein synthesis
To examine the significance of PDCD4 in regulating
myotube mixed protein synthesis, we used RNAi to de-
plete this protein (Figure 5A) and then measured incorp-
oration of phenylalanine into myotube proteins. In fed
cells (Ctl), incorporation of phenylalanine into mixed
proteins in cells deprived of PDCD4 was not different
from the value in those treated with scrambled oligonu-
cleotides (Scrambled siRNA: 2148 ± 165; PDCD4 siRNA
#1: 1924 ± 91, PDCD4 siRNA #2: 1919 ± 115 cps/mg
protein, P > 0.5, Figure 5B). In cells deprived of serum
but supplied with amino acids (i.e., serum-free AMEM),
phenylalanine incorporation into proteins in cells treated
with PDCD4 siRNA #1 was 86% of values in those treated
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Figure 4 Interaction of PDCD4 with eIF4A or eIF4G in myotubes. Myotubes were incubated in differentiation (Ctl) or starvation (serum- and
amino acid-free) medium for 12 h. They were then harvested (Stv) or refed in the differentiation medium in the presence of rapamycin for 1 or
3 h. Lysates were immunoprecipitated with either (A) anti eIF4A or (C) anti PDCD4 antibodies followed by western blotting. Signals from
immunoprecipitates were quantified and shown in B, D and E. Means ± SE; n = 4; bars with different letters differ (P < 0.05).
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Figure 5 Phenylalanine incorporation into proteins in
myotubes depleted of PDCD4. (A) PDCD4 abundance in cells
treated with scrambled siRNA or siRNA oligonucleotides designed
against PDCD4. (B) Cells treated with scrambled (SC) or PDCD4
siRNA #2 were cultured in differentiation (Ctl) or serum-free medium
(Stv) for 12 h. Phenylalanine incorporation into proteins was then
measured. Within each nutrition group, cells depleted of PDCD4
were compared to those treated with scrambled siRNA using paired














































































Figure 6 Phenylalanine incorporation into proteins in
myoblasts and myotubes depleted of PDCD4. (A) L6 myoblasts
were treated with scrambled (SC) or PDCD4 oligonucleotides as
described in Figure 5. Cells were then deprived of amino acids and
serum for 12 h, after which phenylalanine incorporation into
proteins was measured. (B) Myotubes were treated as in Figure 5
except that siRNA oligonucleotides obtained from Life Technologies
were used. Data are expressed as % of SC. Means ± SE of 3–4
independent experiments.
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of those treated with scrambled siRNA (P = 0.00035,
Figure 5B). In another experiment, PDCD4 deprived
cells were incubated in medium lacking both serum and
amino acids (RPMI 1640). Incorporation of phenylalan-
ine into myotube total mixed proteins in cells treated
with the two PDCD4 siRNA oligonucleotides was 72-
80% of the values in cells treated with scrambled siRNA
oligonucleotides (data not shown). Finally we examined
the effect of PDCD4 on the regulation of myofibrillar
proteins. Depletion of PDCD4 led to a 30% reduction in
phenylalanine incorporation into myofibrillar proteins
(see Additional file 2).
The finding of reduced protein synthesis in cells de-
prived of PDCD4 was surprising given the inhibitory role
of this protein on mRNA translation and our previous
finding in myoblast. Thus we carried out two additional
control experiments. First, we repeated the myoblast
experiments and showed that as before, in starved cells,
PDCD4 depletion increased protein synthesis by 43%
(Figure 6A). Finally, we used siRNA oligonucleotides
purchased from another company (Life Technologies,Burlington Ontario Canada) to silence PDCD4 in myo-
tubes. Protein synthesis in myotubes deprived of PDCD4
was reduced by 21% (P = 0.07, Figure 6B).
To gain insight into the mechanisms of effect of PDCD4
knockdown on myotube protein synthesis, we examined
the regulation of components of mTORC1 signalling and
mRNA translation initiation. Although starvation predict-
ably reduced the phosphorylation of 4E-BP1 and increased
the binding of 4E-BP1 to eIF4E, PDCD4 depletion had
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Figure 7 Abundance of translation initiation factors and interaction of eIF4G with eIF4E in myotubes depleted of PDCD4. Cells were
treated with scrambled (SC) or PDCD4 oligonucleotides as in Figures 5 and 6. They were then deprived of amino acids and serum for 12 h.
(A) Abundance of 4E-BP1 and eIF4E, and interaction of the two were measured. Reduced phosphorylation of 4E-BP1 is obvious in downward
shifts of signals in lanes for starved cells (compare lanes 1 and 2 to lanes 3 and 4 in the top panel of Figure 7A). (B) Abundance of eIF4G and its
interaction with eIF4E. (C) Quantification of eIF4G abundance (upper chart; tubulin served as loading control) and its interaction with eIF4E (lower). Data
are expressed as % of SC. Means ± SE of 3 independent experiments.
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S6K1 or S6 phosphorylation (data not shown). However,
there was a trend towards reduced eIF4G in cells depleted
of PDCD4 (17% lower compared to Scramble, P = 0.09).
Furthermore, PDCD4 depletion significantly reduced
eIF4G interaction with eIF4E (Figure 7B and C).
Discussion
In this study, we demonstrated that in myotubes, the regu-
lation of PDCD4 abundance was reversibly modified by a
starvation-refeeding cycle. Collectively, the data presented
here are the first evidence to demonstrate a requirement
for mTORC1 and the proteasome in regulating the abun-
dance of PDCD4 in muscle cells. We also presented evi-
dence that, at least in myotubes, in the absence of growth
factors, amino acids had little effect in regulating the
abundance of this protein. Finally, in starved myotubes,
and contrary to observations in myoblasts [20] and non
muscle cells [12], depletion of PDCD4 had minimal effect
on the incorporation of phenylalanine into myotube pro-
teins. Rather, in starved myotubes, PDCD4 depletion fur-
ther reduced eIF4G binding to eIF4E.
In spite of the fact that PDCD4 has been characterized as
a substrate of S6K1 and an inhibitor of cap-dependent
mRNA translation initiation, there is a paucity of informationon the significance of PDCD4 in skeletal muscle. Also, it
is unknown if the regulation of PDCD4, like mTORC1/
S6K1, is sensitive to nutrients. In the present study, Ser67
and Ser457 phosphorylation of PDCD4 correlates poorly
with its abundance. A requirement for mTORC1/S6K1
in regulating PDCD4 abundance suggests that PDCD4
may be phosphorylated on additional residues. However,
PDCD4 degradation appears to depend specifically on
Ser67 phosphorylation [12]. It is also possible that phos-
phorylated PDCD4 does not accumulate because degrad-
ation by the proteasome is very rapid. However, in refed
cells treated with MG132, Ser67 phosphorylated PDCD4
did not accumulate to a greater extent in comparison with
cells not treated with the drug (data not shown).
Although amino acids can activate mTORC1 [23,24],
the effects of amino acids require some amount of insulin
[25-28]. Our finding that leucine or a medium that con-
tained all the 20 amino acids but lacked growth factors
had insignificant effects on PDCD4 abundance is consist-
ent with this view. AKT too may phosphorylate PDCD4
and target it for degradation [29]. In fact, a require-
ment for serum rather than amino acids might implicate
AKT rather than mTORC1/S6K1 in the phosphorylation
and degradation of PDCD4 since AKT does not require
amino acid for its activation [30]. However, incubation
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but should lead to a greater activation of PI3K-AKT path-
way due to the loss of negative inhibition conveyed by ac-
tivated S6K1 (reviewed in [31]). In our study, the fact that
inhibition with rapamycin during a 1-h refeeding com-
pletely prevented the disappearance of PDCD4 clearly sug-
gests that mTORC1/S6K1 is the main pathway that
targets PDCD4 for degradation in myotubes.
Our data showing that PDCD4 knock down sup-
pressed incorporation of phenylalanine into myotube
mixed proteins are surprising, given the characterization
of the protein as an mRNA translation initiation inhibitor.
Furthermore, depletion of PDCD4 in myoblasts ([20] and
Figure 6) and in non muscle cells [12] increases protein
synthesis. A possible explanation might be that the regula-
tion of myofibrillar proteins, the predominant proteins in
myotubes, is different from that of total protein. However,
we showed that incorporation of phenylalanine into myo-
fibrillar proteins in cells depleted of PDCD4 was 30%
lower compared with cells with normal level of PDCD4
(see Additional file 2). We did not measure the rate of syn-
thesis of sarcoplasmic proteins; nevertheless, our data
showing a suppression of phenylalanine incorporation into
total and myofibrillar proteins suggest that even if deple-
tion of PDCD4 increased the synthesis of sarcoplasmic
proteins, such an increase was likely too small to offset the
decrease in myofibrillar protein synthesis. It is not clear
how PDCD4 depletion would regulate eIF4G abundance
and interaction with eIF4E, although there is evidence that
PDCD4 can transcriptionally regulate the abundance of
some proteins [11]. However, there is no evidence that
eIF4G is one of such proteins.
Combined with data from myoblasts and non muscle
cells, our data suggest that the effect of PDCD4 on protein
synthesis may depend on cell type and/or stage of de-
velopment, as previously suggested [22]. In this regard,
although PDCD4 has been implicated in regulating the
abundance of some proteins, including p21 (Waf1/Cip1)
[32] and lysyl oxidase [33], only c-myb [34], procaspase-3
[35] and p53 [36] have been demonstrated as natural
mRNA translation substrates of PDCD4. These are all fac-
tors involved in regulating cell proliferation and migration,
and therefore of more relevance in proliferating cells. This
is consistent with the notion that the effect of PDCD4 on
mRNA translation and protein synthesis might depend on
the physiological state of the cell. However, PDCD4 and
its targets may still be relevant in regulating muscle pro-
tein synthesis and mass during muscle development and
regeneration. For example during muscle hypertrophy or
repair following injury, satellite cells need to be activated,
leading to the proliferation of myoblasts that will subse-
quently fuse to form myotubes [37]. These can then
fuse with existing myofibers or be used to form new fi-
bers [38,39]. PDCD4 might be involved in this regulation.Consistent with this, abundance of PDCD4 increases dur-
ing initiation of L6 differentiation into myotubes (Abdul-
lahi A. and Adegoke O.A.J., unpublished observations).
Conclusions
We showed that in L6 myotubes, the regulation of PDCD4
abundance by nutritional factors is sensitive to mTORC1
and ubiquitin dependent proteolytic system. In the absence
of growth factors, amino acids, including leucine, appear
to play a minor role in regulating PDCD4 abundance.
Unlike in proliferating myoblasts and non muscle cells,
depletion of PDCD4 had, at best, only modest effect on
myotube protein synthesis, indicating that the effect of
PDCD4 in muscle cells is dependent on the physio-
logical state of the cell. Additional studies are needed to




Fetal Bovine Serum (FBS), Horse Serum (HS), Lipofecta-
mine RNAiMax, Opti-MEM medium, and antibiotic/anti-
mycotic reagents were purchased from Life Technologies
(Burlington, Ontario Canada). Amino acid-free medium
(RPMI 1640) was obtained from US Biological (Swampscott
MA, USA). PDCD4 siRNA oligonucleotides, phosphat-
ase and protease inhibitor cocktails were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Alpha Modi-
fication of Eagle’s Medium (AMEM) was obtained from
Wisent (St-Bruno, Quebec, Canada).
Antibodies
Antibodies to eIF4A, eIF4G, phosphorylated (Thr389)
S6K1, and horseradish peroxidase (HRP)-conjugated
secondary antibodies (anti-rabbit and anti-mouse) were
purchased from Cell Signaling Technology (Danvers,
Massachusetts, USA). Antibody against PDCD4 was
from Cell Signaling Technology or Santa Cruz Biotech-
nology (Santa Cruz, California, USA). Antibodies against
phosphorylated (Ser67, Ser457) PDCD4 were from Sigma-
Aldrich or Aviva Systems Biology (San Diego, California,
USA).
Cell culture
L6 myoblasts were cultured in 12-well plates in growth
medium (GM: AMEM supplemented with FBS and
antibiotic-antimycotic agents to final concentrations of 10
and 1%, respectively) until they reached ~80% confluency.
Cells were then shifted into differentiation medium (DM:
AMEM as above except that 2% HS replaced 10% FBS).
Experiments were carried out on day 4–5 of differenti-
ation. For starvation experiments, myotubes were grown
in differentiation medium or starved in amino-acid free,
serum-free medium (amino acid-free RPMI 1640) for
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ine the roles of amino acids and growth factors in regulat-
ing PDCD4 abundance, in some experiments refeeding
was done in incubation media of varied composition. To
examine the requirement for mTORC1 or the ubiquitin
dependent proteolytic system on the regulation of PDCD4,
additional refeeding experiments were carried out in the
presence of inhibitors of these pathways (50 nM rapa-
mycin and 10 μM MG132, respectively) or equivalent
volumes of DMSO. At the end of the experiments, cells
were harvested in a lysis buffer (25 mM Tris, pH 7.5,
1 mM EDTA, 2% (w/v) sodium dodecyl sulphate (SDS),
1 mM DTT, supplemented with protease (10 μl/mL)
and phosphatase (10 μl/mL) inhibitor cocktails).
RNA interference
Myotubes on day 4 of differentiation were transfected
with 30 nM siRNA oligonucleotides designed against
PDCD4 or with a proprietary scrambled oligonucleotide
((Sigma Aldrich, Oakville, Ontario Canada)), using Lipo-
fectamine RNAiMax (Life Technologies) as previously
described [20]. We used the following PDCD4 siRNA oli-
gonucleotides: PDCD4 #1 sense (GUCUUCUACUAU
UACCAUA [dT] [dT]), PDCD4 #1 antisense (5′UAUGG
UAAUAGUAGAAGAC [dT] [dT]), PDCD4 #2 sense
(CUACUAUUACCAUAGACCA [dT] [dT]), and PDCD4
#2 antisense (UGGUCUAUGGUAAUAGUAG [dT] [dT].
Thirty eight hours after transfection, cells were cultured in
DM or starvation medium. Phenylalanine incorporation
into proteins was then measured by assessing the incorp-
oration of radioactive phenylalanine into trichloroacetic
acid (TCA) precipitable proteins [29,40].
Western blotting and immunoprecipitation
Proteins were resolved on 7.5, 10, or 15% SDS-PAGE
(depending on the antigens being studied), transferred
onto polyvinylidene difluoride (PVDF) membranes, which
were then immunoblotted for the indicated antigens, as
previously described [20]. Immunoblot signals were quan-
tified using the Carestream Molecular Imaging software
(version 5.0.2.30, Carestream Health Inc., Rochester, New
York, USA).
To immunoprecipitate eIF4A or PDCD4, myotubes
were cultured in 10-cm plates. Following appropriate
treatments, cells were rinsed in ice-cold PBS and then lysed
in 500 μl of ice-cold lysis buffer (40 mm HEPES (pH 7.5),
120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate,
10 mM glycerol 2 phosphate, 0.5 mM orthovanadate) sup-
plemented with 0.03% CHAPS, 1 mM DTT, 0.5 mM NaV,
1 mM benzamidine, 6.25 mM N-ethyl-maleimide (NEM)
and protease inhibitor cocktail (10 μL/mL). One hundred
micrograms of myotube proteins were combined with ei-
ther anti eIF4A or anti-PDCD4 (Santa Cruz biotechnology)
antibodies and the mix rotated overnight at 4°C. Thefollowing day and in order to precipitate the antigen-
antibody complex, 50 μL of re-suspended BioMag protein
G–bound beads (GE Healthcare, Baie d’Urfe, Quebec,
Canada) were added to each of the immunoprecipitation
tubes and the suspension rocked gently at 4°C for 1 h. The
beads were collected on a magnetic stand (Life Technolo-
gies) and washed 3 times with 0.1 M sodium phosphate
buffer. After the last wash, beads were re-suspended in 1X
SDS-PAGE sample buffer and boiled at 95°C for 2 minutes.
Following a brief centrifugation, eluates were collected,
separated on 10% SDS-PAGE, and blotted for PDCD4 and
eIF4A.
Statistics
Data are presented as means ± SEM. Treatment means
were compared using a one-way analysis of variance
(ANOVA) and differences among individual means
assessed using the Bonferroni multiple comparison test
or, as in Figures 5, 6 and 7, by paired Students T-tests. Ana-
lyses were done using GraphPAD (Version 6, GraphPAD
Software, La Jolla California, USA). The level of significance
was set at P < 0.05.
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Additional file 2: Myofibrillar protein synthesis in L6 myotubes.
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